KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Deferred Revenue: 2010-2020

Historic Current Deferred Revenue for Nektar Therapeutics (NKTR) over the last 10 years, with Dec 2020 value amounting to $2.6 million.

  • Nektar Therapeutics' Current Deferred Revenue fell 68.34% to $2.6 million in Q4 2020 from the same period last year, while for Dec 2020 it was $2.6 million, marking a year-over-year decrease of 68.34%. This contributed to the annual value of $2.6 million for FY2020, which is 68.34% down from last year.
  • Per Nektar Therapeutics' latest filing, its Current Deferred Revenue stood at $2.6 million for Q4 2020, which was down 14.86% from $3.0 million recorded in Q3 2020.
  • In the past 5 years, Nektar Therapeutics' Current Deferred Revenue ranged from a high of $38.0 million in Q4 2017 and a low of $2.6 million during Q4 2020.
  • For the 3-year period, Nektar Therapeutics' Current Deferred Revenue averaged around $16.1 million, with its median value being $16.5 million (2019).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 164.56% in 2017, then plummeted by 80.22% in 2020.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Current Deferred Revenue stood at $14.4 million in 2016, then skyrocketed by 164.56% to $38.0 million in 2017, then plummeted by 35.12% to $24.6 million in 2018, then tumbled by 67.24% to $8.1 million in 2019, then tumbled by 68.34% to $2.6 million in 2020.
  • Its Current Deferred Revenue stands at $2.6 million for Q4 2020, versus $3.0 million for Q3 2020 and $4.3 million for Q2 2020.